Metastatic Breast Cancer Treatment Market By Types (Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy), By End-User (Hospitals, Clinics, Others), By Geography, Size, Share, Global Industry Report, Forecast, 2021-2030

Industry Report and Statistics (Facts & Figures) - Number of Procedure by Type & End-users

The global metastatic breast cancer treatment market size was $17.13 billion in 2021 and is expected to expand at a CAGR of 10.4% to reach $41.74 billion by 2030 during the period 2021-2030. Based on Region, North America held the greatest revenue share in 2021.

Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer cells removed during the biopsy are examined to check the presence of progesterone or estrogen receptor proteins. The hormones, i.e. estrogen and progesterone, encourage cancer growth when they bind to these receptors. If these receptors are present, cancers are classified as hormone receptor-positive or hormone receptor-negative (proteins). Breast cancer develops due to reasons, like BRCA gene mutation and PIK3CA gene mutation etc. Ducts and lobules are the major components of a breast, and everything is held together by the connective tissue which surrounds it. Breast cancer develops where the ducts or lobules are located, and it can spread to other body parts via blood and lymph arteries. Breast cancer is metastasized when it spreads to other body regions. Advanced breast cancer is another word for metastatic breast cancer. Advanced breast cancer is defined in medical terms as breast cancer that has gone beyond the breast to other essential organs in the body, such as the bones, lungs, liver, or brain, to mention a few. Metastatic breast cancer usually develops months or years after a person has finished treatment for an early or locally advanced variety of breast cancer, such as stage I, II, or III. As a result, metastatic breast cancer is also known as distant recurrence.  SUSAN G. KOMEN reported that breast cancer is the most frequent cancer among women worldwide, with more than 2 million new cases expected in 2020. In 2020, over 168,000 women in the United States lived with metastatic breast cancer. 

 

The most commonly prescribed treatments for metastatic breast cancer are chemotherapy and radiation therapy. Both of these treatments help to slow tumour growth. On the other hand, hormone therapy is the most successful treatment since it helps to limit the growth of cancer cells. The metastatic breast cancer treatment market trends like the introduction of more advanced technologies and rising demand for metastatic breast cancer therapies are some of the primary drivers driving the global market's growth.

 

Market Drivers includes Change in lifestyle, growing demand for better screening, diagnosis, and therapy, and increasing public awareness

• Workplace stress has increased as a result of the fast-paced corporate culture, with work from home post COVID-19 adding fuel to the fire. Furthermore, people's sedentary lifestyles have resulted in various health problems. The prevalence of breast cancer has increased due to these factors, which will boost the market for breast cancer therapies. Breast cancer cases have increased due to lack of exercise, overstressed daily schedule, and denying the health issues. According to SUSAN G. KOMEN, more than 287,000 new instances of invasive breast cancer are predicted to be identified in women and 2,700 cases in men in the United States in 2022, with almost 44,000 women and men expected to die from breast cancer in the United States.  If the breast cancer location is discovered and treated early the disease can be cured. According to the National Library of Medicine, stage 4 breast cancer survival rate by age of 50 has a higher recovery rate than older women. Approximately 13% of women diagnosed with stage IV breast cancer live for ten years after their diagnosis. Considering all of these factors, demand for breast cancer medicines has boosted the worldwide breast cancer therapeutics market.

 

• A spike in the number of breast cancer patients has increased the demand for better screening, diagnosis, and therapy. Breast cancer is diagnosed most frequently among American women. According to breastcancer.org, breast cancer will account for around 30% of newly diagnosed malignancies in women by 2022. Furthermore, as of 2021, breast cancer was the most frequent cancer worldwide, accounting for 12% of all new cancer cases. The general public's knowledge of breast cancer is growing, which has boosted sales of various cancer treatment drugs like tamoxifen, fulvestrant (faslodex), capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, aromatase inhibitors, pegylated, epirubicin, eribulin, fluorouracil, gemcitabine, ixabepilone, methotrexate, nab-paclitaxel, paclitaxel, vinorelbine.

 

• Also, it has led to the advent of various therapies like tumour-agnostic treatment, HER2-targeted therapy, ovarian suppression, whole brain radiation therapy, immunotherapy, stereotactic radiosurgery, fractionated stereotactic radiation therapy which are ultimately contributing to the growth of the industry. Many major players in the breast cancer therapeutics market invest in research and development to develop novel medications and treatment strategies (e.g., blood test for tumour markers) for the disease.

 

Market Restraints: - (High treatment cost, lack of effective treatments, and side effects) 

• The lack of effective treatments and treatment-related adverse effects could limit the growth of the metastatic breast cancer treatment market. The high expense of metastatic breast cancer therapy may also impede the market expansion.

 

Report Opportunities Covers Improvement in reimbursement policies, increasing investment in R&D, rising government support

• The increased investments in research & development and increasing cancer diagnostics awareness campaigns are expected to assist this market to grow significantly in the upcoming years. In the case of postmenopausal women with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, ribociclib plus endocrine therapy showed a significant overall survival benefit, according to a randomized phase 3 trial funded by Novartis. Initially, the findings were presented at the European Society for Medical Oncology Congress 2021 and were communicated through The New England Journal of Medicine.

 

• The market is also expected to rise as reimbursement policies has improved significantly. Because of the vast patient pool, government initiatives, and government financing to discover innovative medicines and improve healthcare conditions, the Asia-Pacific market is predicted to grow at the fastest rate. Breast cancer samples collected from women under 45 years of age were subjected to a genetic study by University of Melbourne researchers. They've discovered a new pharmacological target to help these young ladies have a better prognosis. The Morrison government is giving more than $4.9 million to researchers for a clinical trial to assess these novel medicines. Furthermore, University of Novel South Wales researchers are focusing on treatment-resistant triple-negative breast cancer, where new medicines are desperately needed to increase survival rates. The researchers will test this new medicine in a clinical trial with over $670,000 in government financing.

Global Metastatic Breast Cancer Treatment Market Analysis Of Different Segmentations:

The industry segmentation analysis is based on Types, Application, and Region.

Based on Types

• Chemotherapy

• Radiation Therapy

• Biologic Targeted Therapy

• Breast Surgery

• Hormone Therapy

 

Based on End-User

• Hospitals

• Clinics

• Other

 

Based on Region

North America

• The U.S. 

• Canada

 

Europe

• Germany

• Italy

• France

• The U.K.

• Spain

• Russia

• Rest of Europe

 

Asia Pacific

• China

• India

• Japan

• Rest of APAC 

 

Latin America 

• Argentina

• Mexico

• Brazil 

• Rest of Latin America

 

The Middle East and Africa

• S. Africa

• Rest of MEA

 

Based on the type, radiation therapy and chemotherapy are the most common treatments for metastatic breast cancer since they help to slow the tumour’s growth. According to Cancer World magazine, from 9.8 million in 2018 to 15 million in 2040, the number of patients requiring first-line chemotherapy would grow by 53%. 67% of these patients (10.1 million) will live in low- and middle-income countries by 2040. Chemotherapy was necessary in 57.7% of new cancer cases (9.8 million out of 17 million) worldwide in 2018. In 2040, there will be 26 million new cancer cases, with 53% (15 million) of those requiring chemotherapy (an increase of 5.2 million new cancer cases from 2018). Chemotherapy is more frequently used to treat breast cancers in the middle or late stages. The 5 year survival rate for patients diagnosed in stage 1 is around 90 %. The 5 year life expectancy for breast cancer patients identified at stage 4 is 26 %. Hormone therapy for premenopausal women is becoming the most popular treatment since it slows cancer cell proliferation. The market share of the Metastatic Breast Cancer industry is predicted to expand due to this therapy. 

 

Based on the end-users, the growing number of hospitals and clinics in developing nations, as well as the availability of extensive medical instruments portfolio for treatment and procedures (uses of monoclonal antibodies), the availability of various metastatic breast cancer treatment drugs (small molecule inhibitors), hospitals and clinics are at the forefront of the global industry. However, the number of cancer research centres and laboratories has increased dramatically, owing to the significant funding from both the government and private companies worldwide. On 13th October 2021, Susan G. Komen for the Cure, the world's largest breast cancer charity, said it had awarded $1.5 million to three new research initiatives focusing on metastatic breast cancer (MBC). The awards are part of the Susan G. Komen Metastatic Breast Cancer Collaborative Research Initiative, a ground breaking partnership between Komen, UNC School of Medicine, and Duke Cancer Institute. The initiative aims to make an alliance among the researchers from the above three organizations to address critical gaps in our understanding of MBC to enhance patient care and outcomes. 

 

Based on the region, because of rising healthcare investment, which is backed by prominent healthcare service providers, and the increased prevalence of cancer in the region, North America held the greatest metastatic breast cancer treatment industry share in 2021. In addition, countries in North America, such as the United States, are pushing breast cancer patient awareness programs, which is projected to contribute to the region's industry growth. As the incidence of cancer rises, the need for metastatic breast cancer therapy in North American countries is likely to rise. Breast cancer impacts more than 3.8 million American women, according to the Breast Cancer Organization's data as of January 2022. According to statistics, breast cancer is expected to account for roughly 30% of newly diagnosed cancers among women in 2022. The Asia Pacific market, due to increased breast cancer prevalence and a growing senior population in the region, is expected to develop at the fastest CAGR over the forecast period. Alternatively, due to its demonstrated performance in technology development and a high prevalence of breast cancer in the region, the European market is expected to hold a considerable proportion of the global metastatic breast cancer treatment market. With the rising number of breast cancer deaths, R&D activities to create new treatments for the industry are predicted to expand. WHO's Global Breast Cancer Initiative (GBCI) aims to minimize global breast cancer mortality by 2.5 % each year between 2020 and 2040, avoiding 2.5 million breast cancer deaths. Lowering breast cancer mortality by 2.5 % per year will prevent 25% of breast cancer deaths in women under 70 by 2030 and 40% by 2040.

 

Report Attribute	Details
Forecast Period	2021 - 2030
Market size value in 2021	USD 17.13 billion
Revenue forecast in 2030	USD 41.74 billion
Growth rate	CAGR of 10.4%
The base year for estimation	2021
Historical data	2015 – 2019
Unit	USD Billion, CAGR (2021 - 2030)
Segmentation	By Type, By End User, By Region
By Type	Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy
By End-User	Hospitals, Clinics, Other
By Region	Asia Pacific, North America, Europe, Latin America, The Middle East and Africa
Country Scope	US, Mexico, Canada, Germany, UK, France, China, Japan, India etc.
Company Usability Profiles	AstraZeneca, Bayer, Sun Pharmaceutical, Eli Lilly, Pfizer, Novartis, Merck, Roche, GlaxoSmithKline

 

Global Metastatic Breast Cancer Treatment Market A 360-Degree Analysis Of Competitive Landscape 

The competitive landscape analysis gives an overview of some prominent players operating in the industry. Product innovation and continued R&D operations to create sophisticated technologies have assisted the market growth. In the target market, some of the leading metastatic breast cancer treatment companies are:

• Gilead Sciences

• AstraZeneca

• Bayer

• Sun Pharmaceutical

• Eli Lilly

• Pfizer

• Novartis

• Merck

• Roche

• GlaxoSmithKline

• Johnson & Johnson

 

Recent Developments of the Industry

• On April 2022, Enhertu (trastuzumab deruxtecan), a collaboration between AstraZeneca and Daiichi Sankyo, has received Breakthrough Therapy Designation (BTD) in the United States for the treatment of adults with metastatic HER2-low breast cancer who have gone through prior systemic therapy in the metastatic setting or who have developed disease re-occurrence during or within six months of completing adjuvant chemotherapy. The therapy can be applied to patients having hormone receptor-positive breast cancer should have had endocrine therapy else they are ineligible for it. AstraZeneca and Daiichi Sankyo are working to develop and commercialize Enhertu, a precisely tailored HER2-directed antibody-drug conjugate (ADC).

 

• On October 2021, Researchers at Sunnybrook Health Sciences Centre in Toronto, Canada researched that magnetic resonance (MR)-guided focused ultrasound can safely administer antibody treatment to breast cancer patients who have metastasized to the brain in a first-in-the-world clinical trial. Sunnybrook researchers captured images of trastuzumab (or Herceptin), an antibody therapy, precisely targeting tumours in the brain after using Insightec's Exablate Neuro focused ultrasound device to temporarily and non-invasively open the blood-brain barrier (BBB) and allow intravenous trastuzumab to more effectively access tumour sites in this Phase I clinical trial for Her2-positive breast cancer patients.

 

• On April 2021, Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) gained regular FDA approval for patients with metastatic triple-negative breast cancer (mTNBC) who have got two or more prior systemic treatments, at least one of which was for metastatic illness. Sacituzumab govitecan got accelerated approval in April 2020 for patients with mTNBC who had previously had at least two treatments for metastatic illness.

 

Various metastatic breast cancer treatment commercial products that the market leaders are manufacturing are:

Name	Feature	Key Player
IBRANCE	IBRANCE got the approval for treating adult patients with HR+, HER2- advanced or metastatic breast cancer along with an aromatase inhibitor as first-line endocrine therapy in postmenopausal women or men or patients medicated with fulvestrant who have progressed after endocrine therapy.	Pfizer
KEYTRUDA	It can be used to treat people with an elevated risk of early-stage triple-negative breast cancer as a neoadjuvant treatment along with chemotherapy, then as a single agent as an adjuvant treatment after surgery.	MERCK
Lynparza	It's a targeted therapeutic approach tested in patients with an inherited BRCA mutation having HER2-negative early and metastatic breast cancer.	AstraZeneca